13F GuideFiling Basics
What is SEC Form 13F? Ultimate Guide to Institutional Equity Filings
Learn how SEC Form 13F filings work, the $100M threshold, 45-day reporting lag, and how to track top hedge fund holdings.
AlphaSMO Research GuideRead Guide
CIK: 0001622627
Total reported value
$269.2M
$269.2M
34 檔
13.0%
As reported in its official Q1 2024 Form 13F filing, Rosalind Advisors, Inc.'s tracked investment portfolio stood at $269.2M with 34 total positions.
During Q1 2024, Rosalind Advisors, Inc.'s portfolio maintained high stability with no major positional turnover, reflecting a continuous long-term holding approach.
| # | Ticker | Issuer | Asset Subclass | Weight | Weight Change | Shares Change | 4Q Trend |
|---|---|---|---|---|---|---|---|
| 1 | MYO | Myomo Inc | Stock-Other | 7.48% | +0.37% | +27.49% | |
| 2 | LYRAGBP | Lyra Therapeutics Inc | Stock-Other | 6.65% | — | -39.40% | |
| 3 | ✓ | Mediwound LTD | Stock-Other | 6.47% | -0.76% | -19.90% | |
| 4 | ✓ | Optinose Inc | Stock-Other | 6.20% | — | -7.04% | |
| 5 | XERS | Xeris Biopharma Holdings Inc | Stock-Other | 5.82% | +1.03% | -20.42% | |
| 6 | CMPS | Compass Pathways PLC | Stock-Other | 5.71% | — | -8.08% | |
| 7 | CYBNEUR | Cybin Inc | Stock-Other | 5.39% | — | — | |
| 8 | ABVX | Abivax Sa-adr | Stock-Other | 5.06% | +1.03% | NEW | |
| 9 | VRDN | Viridian Therapeutics Inc | Stock-Other | 4.91% | -1.97% | EXIT | |
| 10 | DCTH | Delcath Systems Inc | Stock-Other | 4.63% | +3.13% | — | |
| 11 | PROF | Profound Medical CORP | Stock-Other | 4.25% | -0.11% | — | |
| 12 | VRNA | Verona Pharma PLC - Adr | Stock-Other | 3.76% | — | — | |
| 13 | CLSDUSD | Clearside Biomedical Inc | Stock-Other | 3.71% | — | — | |
| 14 | ONSGBP | Outlook Therapeutics Inc | Stock-Other | 3.48% | — | — | |
| 15 | 4XC1 | Kalvista Pharmaceuticals Inc | Stock-Other | 3.19% | — | -4.00% | |
| 16 | TRVI | Trevi Therapeutics Inc | Stock-Other | 2.99% | — | -50.28% | |
| 17 | VERUEUR | Veru Inc | Stock-Other | 2.94% | — | +12.50% | |
| 18 | ✓ | Stock-Other | 2.42% | — | — | ||
| 19 | CLRBUSD | Cellectar Biosciences Inc | Stock-Other | 2.31% | — | -69.01% | |
| 20 | ✓ | Polypid LTD | Stock-Other | 1.79% | -0.32% | — | |
| 21 | NSPR | Inspiremd Inc | Stock-Other | 1.52% | -1.54% | -25.85% | |
| 22 | EYEGEUR | Kiora Pharmaceuticals Inc | Stock-Other | 1.52% | — | — | |
| 23 | ✓ | Beyond Air Inc | Stock-Other | 1.47% | — | — | |
| 24 | CARAEUR | Cara Therapeutics Inc | Stock-Other | 1.32% | — | — | |
| 25 | FBIO | Fortress Biotech Inc | Stock-Other | 1.14% | — | — | |
| 26 | SPRU | Spruce Power Holding Corporation | Stock-Other | 1.11% | — | -4.92% | |
| 27 | TLPH | Talphera Inc | Stock-Other | 0.73% | +0.97% | — | |
| 28 | BFRI | Biofrontera Inc | Stock-Other | 0.73% | +0.07% | — | |
| 29 | GERN | Geron CORP | Stock-Other | 0.62% | — | — | |
| 30 | RZLT | Rezolute Inc | Stock-Other | 0.48% | — | — | |
| 31 | TNXPEUR | Tonix Pharmaceuticals Holdin | Stock-Other | 0.16% | — | — | |
| 32 | XBI | Ss Spdr S&p Biotech ETF | ETF-Tech | 0.07% | — | -90.00% | |
| 33 | ✓ | Invesco QQQ Tr Put Option 06/2 | Stock-Other | 0.01% | -0.42% | EXIT | |
| 34 | ✓ | Amylyx Pharmaceuticals Inc | Stock-Other | — | — | — |
According to official SEC Form 13F filings, Rosalind Advisors, Inc. reported a total U.S. public equity portfolio value of $269.2M across 34 disclosed positions in Q1 2024.
Expert Analysis & Guides for Tracking Wall Street Smart Money Movements
Learn how SEC Form 13F filings work, the $100M threshold, 45-day reporting lag, and how to track top hedge fund holdings.
In terms of portfolio concentration, the top 5 core holdings (including MYO, LYRAGBP, MEDIWOUND LTD) accounted for 13.0% of total reported equity market value during Q1 2024.
During Q1 2024, Rosalind Advisors, Inc.'s top holdings by market value included MYO (7.5%)、LYRAGBP (6.7%)、MEDIWOUND LTD (6.5%). The largest single position, MYO, represented 7.5% of total portfolio value.
In Q1 2024, Rosalind Advisors, Inc. made 0 total portfolio adjustments, initiating 0 new buys, adding to 0 positions, trimming 0 holdings, and fully liquidating 0 stocks.
All holding records on this page are fetched directly from the U.S. Securities and Exchange Commission (SEC) EDGAR system (Form 13F-HR). AlphaSMO parses CUSIP identifiers and formats data into Schema.org-compliant datasets.
Understand SEC Form 4 insider disclosures for corporate officers, directors, and 10% owners to track executive transactions.
Understand Rule 144 restricted stock sale notices to spot planned insider liquidations before market sell pressure arrives.
Explore the 5% beneficial ownership threshold, 13D vs 13G filing differences, and recent SEC accelerated deadline rules.
Best practices for analyzing 13F quarterly changes without getting misled by stock splits, options, or market valuation drift.
Learn how AlphaSMO's flagship signal detects high-conviction stocks where 13F hedge funds and corporate insiders buy at the same time.